Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Open accessPublished version of a preprint
The DOI matches its Crossref record; 54 of the 60 references it cites were found in a registry or an index, and 4 are not checked yet; 12 of the 42 sources its claims cite were checked for support.
Abstract
Covalent inhibitors of KRASG12C have shown antitumor activity against advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and additional strategies are needed to improve outcomes. JDQ443 is a structurally unique covalent inhibitor of GDP-bound KRASG12C that forms novel interactions with the switch II pocket. JDQ443 potently inhibits KRASG12C-driven cellular signaling and demonstrates selective antiproliferative activity in KRASG12C-mutated cell lines, including those with G12C/H95 double mutations. In vivo, JDQ443 induces AUC exposure-driven antitumor efficacy in KRASG12C-mutated cell-derived (CDX) and patient-derived (PDX) tumor xenografts. In PDX models, single-agent JDQ443 activity is enhanced by combination with inhibitors of SHP2, MEK, or CDK4/6. Notably, the benefit of JDQ443 plus the SHP2 inhibitor TNO155 is maintained at reduced doses of either agent in CDX models, consistent with mechanistic synergy. JDQ443 is in clinical development as monotherapy and in combination with TNO155, with both strategies showing antitumor activity in patients with KRASG12C-mutated tumors. Significance: JDQ443 is a structurally novel covalent KRASG12C inhibitor with a unique binding mode that demonstrates potent and selective antitumor activity in cell lines and in vivo models. In preclinical models and patients with KRASG12C-mutated malignancies, JDQ443 shows potent antitumor activity as monotherapy and in combination with the SHP2 inhibitor TNO155. See related video: https://vimeo.com/720726054 This article is highlighted in the In This Issue feature, p. 1397
Verified 2026-10-06 · 4 references not checked yet
Overview
CoChat Summary
TL;DR
JDQ443 is a structurally novel, orally bioavailable covalent inhibitor of GDP-bound KRASG12C with a distinct switch II pocket binding mode, potent mutant-selective preclinical activity, and early clinical responses alone and with the SHP2 inhibitor TNO155. Preclinical efficacy is driven by daily AUC and sustained KRASG12C target occupancy, and combinations improve single-agent activity in NSCLC and colorectal cancer models.
Key findings
- JDQ443 covalently and selectively binds GDP-bound KRASG12C: biochemical kinact/Ki was 141 (5.1) [34], with low reversible binding affinity to RAS WT paralogs in the GDP-bound state and all GMPNP-bound affinities >200; cellular cRAF recruitment IC50 was 0.012 (0.0008) for KRASG12C versus >1 for KRASWT, NRASWT, and HRASWT (Table 1).
- JDQ443 selectively inhibited KRASG12C-mutated cell lines in a 242-line CCLE panel (17 KRASG12C-mutant, 225 non–G12C-mutant) and showed proteome-wide selectivity by competing >2-fold with the KRAS cysteine-12 peptide among >11,500 cysteine-containing peptides, with eight additional cysteine residues on six proteins showing similar competition.
- In CDX models, JDQ443 produced dose-dependent antitumor activity ranging from regression (MIA PaCa-2, LU99) to stasis (HCC44, NCI-H2122) to moderate inhibition (NCI-H2030, KYSE410), with no growth inhibition in a KRASG12V-mutated NCI-H441 model; efficacy correlated with daily AUC and KRASG12C target occupancy rather than Cmax or time over threshold.
- JDQ443 plus TNO155 improved single-agent activity; in LU99 and HCC44, JDQ443 30 mg/kg q.d. plus TNO155 7.5 mg/kg b.i.d. achieved the same response as single-agent JDQ443 100 mg/kg q.d., and in KYSE410 the combination achieved tumor stasis. Two clinical cases showed RECIST 1.1 partial responses: −30.4% on JDQ443 monotherapy 200 mg b.i.d. in KRASG12C-mutated NSCLC, and −44.2% on JDQ443 200 mg q.d. plus TNO155 20 mg q.d. in KRASG12C-mutated duodenal papillary cancer.
Methods
- Discovery used structure-based de novo design, SAR optimization, cocrystal structures, and an MS-based screen of 3,315 molecules yielding 107 confirmed hits with single KRASG12C target modification and >50% modification after 2 hours at 50 μmol/L; glutathione reactivity was used to assess promiscuous cysteine reactivity.
- Preclinical characterization included biochemical covalent competition and surface plasmon resonance assays, NanoBiT KRAS:cRAF recruitment, pERK and proliferation assays, CCLE cell-line profiling, LC/MS tandem mass tag cysteine proteomics, Ba/F3 KRASG12C second-site mutants, CDX and PDX mouse studies, PK/PD modeling, continuous intravenous infusion, and 1 × 1 × 1 mouse clinical trial PDX panels.
- Clinical data came from the phase Ib/II KontRASt-01 trial (NCT04699188), an open-label, multicenter dose-escalation and -expansion study of JDQ443 alone or with TNO155 and/or tislelizumab in adults with KRASG12C-mutated solid tumors; two illustrative cases are reported.
Limitations
- The paper states that in the PDX panels, sample size did not enable conclusive correlations between genetic comutations and efficacy.
- The paper states that phase I studies present a high risk of patient reidentification, so individual patient results cannot be shared, and some clinical data are subject to contractual or consent restrictions.
- Evident from the text: clinical activity is illustrated by only two cases from an ongoing trial, with no mature safety, efficacy, or randomized comparison data; preclinical efficacy relies on mouse CDX/PDX models, and resistance testing covers selected KRASG12C second-site mutants rather than the full diversity of clinical resistance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Design of JDQ443 and its binding mode to KRASG12C. A, Scheme of the design concept to maintain the indazole and the phenyl acrylamide pharmacophores and design a scaffold to link them. Several scaffolds were evaluated in silico and the best group (dimethyl pyrazole) selected for synthesis [3] and further optimized to give JDQ443 ([5]; see Supplementary Table S1). B, Crystal structure of JDQ443 monomer 1 in complex with KRASG12C. H-bonds are shown as yellow dotted lines. The indazole moiety forms H-bond interactions with the side chain of D69 and the backbone amide donor of S65 as well as fills the hydrophobic region delimited by V103, I100, M72, and Q99 (Cα and Cβ). The pyrazole is positioned at ∼60° to the indazole fragment with the methyl pointing toward R68, T58, M72, and V9. In addition, it forms edge-to-face interactions with Y96. The spirocyclic group is a rigid linker optimally orienting the acrylamide toward C12 and the amide carbonyl to form hydrogen bond interactions with the side chain of K16 and water-mediated interaction to the Mg2+ ion and the beta phosphoryl group of GDP. The methyl–indazole moiety is almost planar to the pyrazole, and it is sandwiched between the switch II and the Q99 side chain (black dotted lines). Major differences between the two JDQ443 monomers are the conformation of H95 (pointing toward the ligand in monomer 2; Supplementary Fig. S3) and the interactions of the methyl–indazole moiety.](https://figures.cochat.ai/paper-figures/69b86444b76d4318bc142d35abbeee11/discovery-preclinical-characterization-and-early-clinical-activity-of-jdq443-a-figure-1.jpg)

![Figure 3. JDQ443 displays antitumor activity across a range of cell-derived, KRASG12C-dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRASG12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRASG12C-mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRASG12C-mutated (C–G) and non–G12C-mutated (NCI-441, KRASG12V; B) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a programmable microinfusion pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood (H) and average free KRASG12C levels in tumor at steady state (I) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.](https://figures.cochat.ai/paper-figures/ba47da11a56e4199845bb57b3b285bb0/discovery-preclinical-characterization-and-early-clinical-activity-of-jdq443-a-figure-3.jpg)



Verification
Claims the paper makes
9 Valid · 1 Not valid · 13 Not checked · 98 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“was recently found to be targetable by small-molecule inhibitors (8, 9).”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > INTRODUCTION
What the sources say
- Supportedcites [8] Lim, 2014, Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor, Angew Chem Int Ed Engl source
The Abstract of our copy states that SML-8-73-1 (a GDP analogue bearing an electrophilic chloroacetamide) and its prodrug SML-10-70-1 are 'selective, direct-acting covalent inhibitors of the K-Ras G12C mutant relative to wild-type Ras' and that these 'first-in-class covalent K-Ras inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy'. A Results passage (p. ~4, EC50 6.6 nM labeling of K-Ras G12C) and the cellular target-engagement experiment in H358 cells further show the mutant is engaged by a small molecule in a cellular context. This directly supports the attributed point that KRAS G12C is targetable by small-molecule inhibitors (the paper's own caveats about cell permeability do not negate targetability). (LLM, conf=0.90)
- Supportedcites [9] Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature source
The Abstract of Ostrem et al. (2013) states 'Here we report the development of small molecules that irreversibly bind to a common oncogenic mutant, K-Ras(G12C)', relying on the mutant cysteine and sparing wild-type protein, and concludes that the new allosteric site (S-IIP) 'is targetable in a mutant-specific manner'. The Discussion confirms identification of the S-IIP pocket and 'irreversible, mutant-specific inhibitors of Ras function', with cellular data in G12C-containing lung cancer cell lines (compound 12, EC50 0.32 microM in H1792) showing allele-specific impairment. The claim as paraphrased is fully covered by our copy. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the compound ARS-1620 (17), which showed the first in vivo validation in patient-derived mouse models of KRASG12C-mutated NSCLC and PDAC.”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > INTRODUCTION
What the sources say
- Supportedcites [17] Janes, 2018, Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor, Cell source
The Results describe ARS-1620 testing in patient-derived mouse xenografts comprising three KRAS p.G12C NSCLC models and one pancreatic adenocarcinoma model, and report tumor inhibition and regression in the p.G12C models. The Discussion calls the study the first in vivo evidence for this KRASG12C-targeted approach. Page numbers are unavailable in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“JDQ443 antiproliferative activity was assessed by a high-throughput cell viability assay in a large panel of KRASG12C-mutated (N = 17) and non–G12C-mutated (N = 225) cell lines from the Cancer Cell Line Encyclopedia (29). JDQ443 demonstrated potent antiproliferative activity selectively toward the KRASG12C-mutated lines (Fig. 2A and B).”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > RESULTS > JDQ443 Potently Inhibits KRASG12C Cellular Signaling and Proliferation in a Mutant-Selective Manner
What the sources say
- Supportedcites [29] Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature source
The citation is attached to the provenance of the cell-line panel ('cell lines from the Cancer Cell Line Encyclopedia (29)'), not to the JDQ443 selectivity result, which the citing authors report as their own finding (Fig. 2A, B). Our copy identifies itself as that resource: the Abstract (p. 1) describes CCLE as 'a compilation of gene expression, chromosomal copy number, and massively parallel sequencing data from 947 human cancer cell lines' with 'pharmacologic profiles for 24 anticancer drugs across 479 of the lines', and the Methods Summary confirms mutation annotation by targeted sequencing of >1,600 genes plus OncoMap genotyping of recurrent mutations in 33 cancer genes (KRAS among them, per the Fig. 2c/Supplementary Tables 8-9 discussion). The specific N = 17 KRASG12C and N = 225 non-G12C counts are the citing authors' subset definitions and are not attributed to this source, so no qualifier is missing from what is credited here. (LLM, conf=0.85)
boostedstates a causen = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies demonstrating an elevated pool of GDP-bound KRASG12C under SHP2 inhibition (38, 48) provide a rationale for combining JDQ443 and the SHP2 inhibitor TNO155.”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > DISCUSSION
What the sources say
- Partly supportedcites [38] Ryan, 2020, Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition, Clin Cancer Res sourceExperimental — accuracy not yet measured
The Results section reports reduced KRAS-GTP with SHP2 inhibition and stronger suppression when SHP099 is combined with ARS-1620. The Discussion says SHP2 inhibition reduces cycling to the active GTP-bound state and supports combining SHP2 and KRASG12C inhibitors. The paper does not directly demonstrate an elevated GDP-bound KRASG12C pool or test JDQ443 with TNO155. (LLM, conf=0.82)
- Supportedcites [48] Fedele, 2021, SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling, J Exp Med source
The Introduction explains that inhibiting exchange could increase occupancy of KRASG12C-GDP, the form accessible to G12C inhibitors. In the Results (section “SHP2 inhibition enhances KRASG12C inhibitor effects in PDAC and NSCLC cell lines”), SHP2 inhibition accelerated inhibitor binding to KRASG12C, supporting that mechanistic rationale. The cited experiments used SHP099 and ARS1620; the choice of JDQ443 and TNO155 is the citing authors’ proposed application. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Second-site mutations within the SWIIP show distinct sensitivity to adagrasib versus sotorasib depending on the binding mode of the inhibitor (42).”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > DISCUSSION
What the sources say
- Partly supportedcites [42] Koga, 2021, KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments, J Thorac Oncol sourceExperimental — accuracy not yet measured
The Cross Resistance results (p. 6) show that several secondary KRAS mutations have different sensitivities to adagrasib and sotorasib. The Discussion (p. 9) places several mutation sites around the drug-binding pocket and suggests they may impair binding, but does not establish that differences in inhibitor binding mode cause the distinct sensitivities. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims
Create a free account to see all 121 claims and to verify the 30 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 57
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of multiple KRASG12C inhibitors have shown promising efficacy in advanced, previously treated non–small cell lung cancer (NSCLC), leading to United States Food and Drug Administration (FDA) accelerated approval of two of these therapies (adagrasib and sotorasib) and many others being investigated in this setting (9–17).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In order to overcome the resistance of other KRASG12C inhibitors, JDQ-443 covalently binds to the “Switch II pocket” of KRASG12C and irreversibly locks it into an inactive GDP binding state.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [73]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, JDQ-443 in conjunction with the SHP 2 inhibitor TNO-155 has demonstrated a synergistic effect in preclinical animal models, resulting in improved outcomes at lower doses.73”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [73]
In the citing paper
“For example, combinations of G12Ci and SHP2 inhibitors (SHP2i) such TNO155 (14) and RMC-4550 (15) have been validated pre-clinically and are now being explored in the clinic (NCT04699188, NCT05480865).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > RESULTS > JDQ443 Potently Inhibits KRASG12C Cellular Signaling and Proliferation in a Mutant-Selective Manner
“JDQ443 covalently and selectively binds and inhibits GDP-bound KRASG12C with low reversible binding affinity to the RAS switch II pocket, and also inhibits proliferation of KRASG12C-mutated and KRAS G12C/H95, G12C/R68S, and G12C/Y96 double-mutant cell lines”
§ Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C > RESULTS > JDQ443 Potently Inhibits KRASG12C Cellular Signaling and Proliferation in a Mutant-Selective Manner
“whereas expression of G12C/R68S, G12C/Y96C, and G12C/Y96D double mutants conferred resistance to JDQ443.”
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 3×
“In silico Optimization GDP-bound: • KRAS WT • KRAS G12C 0.012 (0.0008) • KRAS G12C 0.018 (0.003) • RAS WT MEK Q56P > 1 • KRAS G12C 0.063 (0.004) • RAS WT MEK Q56P > 1 In order to assess the breadth of mutant selectivity in a cellular setting, JDQ443 antiproliferative activity was assessed by a high-throughput cell via…”
InfluentialNext-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 3×
“…one common KRAS oncogenic variant—a glycine-to-cysteine sub-stitution at amino acid 12 (KRAS G12C ) that occurs in approximately 13% of lung adenocarcinomas, 4% of colon tumors, and smaller fractions of other cancers (7)—was recently found to be targetable by small-molecule inhibitors (8, 9).”
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“18) and adagrasib (MRTX-849; ref.”
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“…nucleotides, an apparent absence of targetable allosteric sites, and the clinical failure of attempts to target other critical aspects of KRAS functioning such as KRAS membrane attachment (6) or inhibition of downstream signaling in the absence of direct selective inhibition of the driver oncogene.”
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“This resulted in replacement of the aniline linker by a spirocyclic azetidine moiety, as represented with [4] (Supplementary Table S1).”
Research works printed but not linked: 1
- Weiss, KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation, Ann Oncol 2021;32(suppl_5):S1283–S1346. Abstract nr LBA6.
Cited by
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“…have shown promising efficacy in advanced, previously treated non–small cell lung cancer (NSCLC), leading to United States Food and Drug Administration (FDA) accelerated approval of two of these therapies (adagrasib and sotorasib) and many others being investigated in this setting (9–17).”
BackgroundChemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1420 · Cited by 203
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 184
Metadata
- Authors
- Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., Fedele, C., Gerspacher, M., Guthy, D. A., Head, V., Jaeger, A., Núñez, E. J., Kearns, J. D., Leblanc, C., Maira, S.-M., Murphy, J., Oakman, H., Ostermann, N., Ottl, J., Rigollier, P., Roman, D., Schnell, C., Sedrani, R., Shimizu, T., Stringer, R., Vaupel, A., Voshol, H., Wessels, P., Widmer, T., Wilcken, R., Xu, K., Zecri, F., Farago, A. F., Cotesta, S., & Brachmann, S. M.
- Affiliations
- Novartis (Switzerland) (CH)
- 2Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
- Novartis (United States) (US)
- 1Novartis Institutes for BioMedical Research, Basel, Switzerland.
- National Cancer Centre Japan (JP)
- Corresponding author
- Farago, Anna F.
- Cotesta, Simona
- ORCID
- Weiss, Andreas
- Lorthiois, Edwige
- Beyer, Kim S.
- Bomio-Confaglia, Claudio
- Burks, Heather
- Chen, Xueying
- Cui, Xiaoming
- de Kanter, Ruben
- Fedele, Carmine
- Guthy, Daniel Alexander
- Head, Victoria
- Núñez, Eloísa Jiménez
- Kearns, Jeffrey D.
- Maira, Sauveur-Michel
- Murphy, Jason
- Ostermann, Nils
- Ottl, Johannes
- Schnell, Christian
- Sedrani, Richard
- Shimizu, Toshio
- Stringer, Rowan
- Vaupel, Andrea
- Voshol, Hans
- Widmer, Toni
- Wilcken, Rainer
- Xu, Kun
- Farago, Anna F.
- Cotesta, Simona
- Brachmann, Saskia M.
- Venue
- Cancer Discovery
- Published
- 2022-04-04
- Volume
- 12
- Issue
- 6
- Pages
- 1500-1517
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC9394399
- OpenAlex
- W4223470164
- Semantic Scholar
- 489eedfd203fc45a3096bde22b30ab39345e0711
- Cited by
- 150
- References
- 60
- Citations by year
- 2026: 24 · 2025: 33 · 2024: 46 · 2023: 43 · 2022: 4
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Incyte
- Eisai
- Astellas Pharma
- PharmaMar
- SymBio Pharmaceuticals Limited
- Genentech
- Chugai Pharmaceutical
- Takeda Oncology
- Loxo Oncology
- Daiichi Sankyo Europe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12C, covalent KRAS inhibitor, switch-II pocket, TNO155, SHP2 inhibitors, combination therapy, patient-derived xenografts, cell line-derived xenografts, anticancer activity, drug resistance, MEK inhibition, CDK4/6 inhibition
- MeSH terms
- Enzyme Inhibitors, Humans, Indazoles, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. https://app.cochat.ai/papers/10.1158/2159-8290.cd-22-0158
- The paper
- Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., Fedele, C., Gerspacher, M., Guthy, D. A., Head, V., Jaeger, A., Núñez, E. J., Kearns, J. D., Leblanc, C., Maira, S.-M., . . . Brachmann, S. M. (2022). Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-22-0158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.